Literature DB >> 15854201

Endothelial dysfunction links erectile dysfunction to heart disease.

M Kirby1, G Jackson, U Simonsen.   

Abstract

Erectile dysfunction (ED) and coronary artery disease (CAD) overlap in risk factors, aetiology and clinical outcomes. It has become clear that ED is an important marker of vascular disease throughout the arterial tree--including CAD, stroke and diabetes. Epidemiological studies have demonstrated a close association between ED and vascular disease. The shared aetiological factor is endothelial dysfunction. The fact that ED tends to precede the onset of symptoms of other vascular diseases--because blood vessels in the penis are narrower in diameter than elsewhere in the body so blood flow is restricted sooner by atherosclerosis--means that it can be used as a 'window' on vascular health. There is growing evidence that patients presenting with ED should be investigated for cardiovascular disease (CVD), including diabetes, even if they have no symptoms. Early detection could facilitate prompt intervention and a reduction in long-term complications. Treatments that reduce endothelial dysfunction offer the potential of improving the functioning of the entire vascular system, improving outcomes in CVD and diabetes, as well as providing effective treatment for ED.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854201     DOI: 10.1111/j.1742-1241.2005.00453.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  26 in total

1.  Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.

Authors:  Thomas G Travison; Susan A Hall; William A Fisher; Andre B Araujo; Raymond C Rosen; John B McKinlay; Michael S Sand
Journal:  J Sex Med       Date:  2011-08-11       Impact factor: 3.802

Review 2.  Emerging role for TNF-α in erectile dysfunction.

Authors:  Fernando S Carneiro; Robert Clinton Webb; Rita C Tostes
Journal:  J Sex Med       Date:  2010-12       Impact factor: 3.802

3.  Usefulness of serum fetuin-A level as a marker of erectile dysfunction.

Authors:  W Kandeel; W El-Shaer; A Sebaey; A A Abou-Taleb; A Fathy; B Elmohamady; A I Mansour
Journal:  Int J Impot Res       Date:  2017-04-20       Impact factor: 2.896

Review 4.  Molecular mechanisms associated with diabetic endothelial-erectile dysfunction.

Authors:  Ângela Castela; Carla Costa
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

5.  Metformin treatment improves erectile function in an angiotensin II model of erectile dysfunction.

Authors:  Hicham Labazi; Brandi M Wynne; Rita Tostes; R Clinton Webb
Journal:  J Sex Med       Date:  2013-07-24       Impact factor: 3.802

6.  Assessment of erectile dysfunction and associated psychological distress in Chinese men with type 2 diabetes mellitus.

Authors:  S Chen; D Peng; X Xu; J Gao; F Dai; C Zuo; Q Zhang
Journal:  Int J Impot Res       Date:  2017-06-29       Impact factor: 2.896

7.  Reversal of diabetic vasculopathy in a rat model of type 1 diabetes by opiorphin-related peptides.

Authors:  Giulia Calenda; Yuehong Tong; Nirmala D Kanika; Moses T Tar; Sylvia O Suadicani; Xinhua Zhang; Arnold Melman; Catherine Rougeot; Kelvin P Davies
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-22       Impact factor: 4.733

Review 8.  The role of opiorphins (endogenous neutral endopeptidase inhibitors) in urogenital smooth muscle biology.

Authors:  Kelvin Paul Davies
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 9.  [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Authors:  H Porst; K Hell-Momeni; H Büttner
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

10.  Additive effects of Artemisia capillaris extract and scopoletin on the relaxation of penile corpus cavernosum smooth muscle.

Authors:  B R Choi; S K Kumar; C Zhao; L T Zhang; C Y Kim; S W Lee; J-H Jeon; K K Soní; I So; S H Kim; N C Park; H K Kim; J K Park
Journal:  Int J Impot Res       Date:  2015-10-08       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.